Wu Dan, Jiang Honglei, Gu Qiuhong, Zhang Dan, Li Zhiwei
Infectious Disease Department, The Shengjing Hospital of China Medical University, Heping District, Sanhao Street No.36, Shenyang, 110004, China.
Tumour Biol. 2013 Oct;34(5):3265-9. doi: 10.1007/s13277-013-0899-4. Epub 2013 Jun 19.
To investigate the association between X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk, we performed a systematic meta-analysis of eligible case-control studies. Eligible studies were identified from the PubMed, Embase, and Chinese National Knowledge Infrastructure databases up to March 2013. The odds ratios (ORs) and corresponding 95 % confidence interval (95 % CI) of XRCC1 Arg399Gln polymorphism in hepatitis virus-related hepatocellular carcinoma cases compared with those in controls were calculated. The meta-analysis was performed using fixed-effect or random-effect methods according to the absence or presence of heterogeneity. This meta-analysis included 1,558 cases with hepatitis virus-related hepatocellular carcinoma and 1,338 controls. Meta-analysis of available data showed that there was no association between XRCC1 Arg399Gln polymorphism and risk of hepatitis virus-related hepatocellular carcinoma under all contrast models (Gln vs. Arg: fixed-effect OR = 0.92, 95 % CI 0.82-1.04, P = 0.18; GlnGln vs. ArgArg: random-effect OR = 0.79, 95 % CI 0.50-1.25, P = 0.32; GlnGln/ArgGln vs. ArgArg: fixed-effect OR = 0.92, 95 % CI 0.79-1.07, P = 0.28; and GlnGln vs. ArgArg/ArgGln: random-effect OR = 0.83, 95 % CI 0.52-1.34, P = 0.45). Sensitivity analysis further showed that there was no association between XRCC1 Arg399Gln polymorphism and risk of hepatitis B-related hepatocellular carcinoma under all contrast models (Gln vs. Arg: fixed-effect OR = 0.93, 95 % CI 0.82-1.05, P = 0.25; GlnGln vs. ArgArg: fixed-effect OR = 0.86, 95 % CI 0.64-1.16, P = 0.32; GlnGln/ArgGln vs. ArgArg: fixed-effect OR = 0.93, 95 % CI 0.80-1.10, P = 0.41; and GlnGln vs. ArgArg/ArgGln: fixed-effect OR = 0.85, 95 % CI 0.63-1.13, P = 0.26). Our meta-analysis of the available data did not find an obvious effect of XRCC1 Arg399Gln polymorphism on hepatitis-related hepatocellular carcinoma. More well-designed studies with large sample are needed to further verify the effect.
为了研究X射线修复交叉互补基因1（XRCC1）Arg399Gln多态性与肝炎病毒相关肝细胞癌风险之间的关联，我们对符合条件的病例对照研究进行了系统的荟萃分析。通过检索截至2013年3月的PubMed、Embase和中国知网数据库来确定符合条件的研究。计算了肝炎病毒相关肝细胞癌病例中XRCC1 Arg399Gln多态性与对照组相比的比值比（OR）及相应的95%置信区间（95%CI）。根据异质性的有无，采用固定效应或随机效应方法进行荟萃分析。该荟萃分析纳入了1558例肝炎病毒相关肝细胞癌病例和1338例对照。对现有数据的荟萃分析表明，在所有对比模型下，XRCC1 Arg399Gln多态性与肝炎病毒相关肝细胞癌风险之间均无关联（Gln与Arg：固定效应OR = 0.92，95%CI 0.82 - 1.04，P = 0.18；GlnGln与ArgArg：随机效应OR = 0.79，95%CI 0.50 - 1.25，P = 0.32；GlnGln/ArgGln与ArgArg：固定效应OR = 0.92，95%CI 0.79 - 1.07，P = 0.28；GlnGln与ArgArg/ArgGln：随机效应OR = 0.83，95%CI 0.52 - 1.34，P = 0.45）。敏感性分析进一步表明，在所有对比模型下，XRCC1 Arg399Gln多态性与乙型肝炎相关肝细胞癌风险之间均无关联（Gln与Arg：固定效应OR = 0.93，95%CI 0.82 - 1.05，P = 0.25；GlnGln与ArgArg：固定效应OR = 0.86，95%CI 0.64 - 1.16，P = 0.32；GlnGln/ArgGln与ArgArg：固定效应OR = 0.93，95%CI 0.80 - 1.10，P = 0.41；GlnGln与ArgArg/ArgGln：固定效应OR = 0.85，95%CI 0.63 - 1.13，P = 0.26）。我们对现有数据的荟萃分析未发现XRCC1 Arg399Gln多态性对肝炎相关肝细胞癌有明显影响。需要更多设计良好的大样本研究来进一步验证其作用。
